NCT03955016UnknownNot Applicable
A Randomized Controlled Trial to Evaluate the Effect of a Rehabilitation Program on the Exercise Capacity of Patients With Pulmonary Hypertension
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- KU Leuven
- Enrollment
- 20
- Locations
- 2
- Primary Endpoint
- Change in functional exercise capacity
Study Overview
Brief Summary
The purpose of this study is to test the impact of a personalized, partly supervised rehabilitation program on the exercise capacity in patients with pulmonary hypertension. The rehabilitation program consists of 2 weeks inpatient, 2 weeks ambulatory and 11 weeks home based rehabilitation.
Detailed Description
The present study is a 15 weeks, randomized (1:1) controlled trial. Patients in both groups will not change their usual medical treatment. After 2 clinical visits (screening and randomization visit), patients in the intervention group will follow a 15 week rehabilitation program consisting of 2 weeks inpatient, 2 weeks outpatient and 11 weeks home based rehabilitation. At the end of the outpatient rehabilitation phase (week 4) and the home-based program (week 15), clinical outcomes will be reassessed.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Masking Description
Outcome assessor will be blinded for the outcome
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Female and male patients ≥ 18 years
- •Pulmonary arterial hypertension (PAH, Group 1 of Nice classification) and chronic thromboembolic pulmonary hypertension (CTEPH, group 4)
- •WHO functional class II-III
- •PH diagnosed by right heart catheter showing:
- •Baseline mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg
- •Baseline pulmonary vascular resistance (PVR) ≥ 240dyn x s x cm-5
- •Baseline pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHgg
- •Patients receiving optimized conventional PH therapy including intensified treatment with diuretics and who have been stable for 2 months before entering the study.
- •Except for diuretics, medical treatment should not be expected to change during the entire 15-week study period.
- •Negative pregnancy test (β-HCG) at the start of the trial and appropriate contraception throughout the study for women with child- bearing potential
- •Able to understand and willing to sign the Informed Consent Form
Exclusion Criteria
- •PH of any cause other than permitted in the entry criteria, e.g. concomitantly to portal hypertension, complex congenital heart disease, reversed shunt, HIV infection, suspected pulmonary veno-occlusive disease based on pulmonary edema during a previous vasoreactivity test or on abnormal findings compatible with this diagnosis (septal lines or pulmonary edema at high resolution computer tomography), congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension or unclear diagnosis
- •Patients with signs of right heart decompensation
- •Walking disability
- •Acute infection, pyrexia
- •Any change in disease-targeted therapy within the last 2 months
- •Any subject who is scheduled to receive an investigational drug during the course of this study
- •Severe lung disease: FEV1/FVC <0.5 and total lung capacity <70% of the normal value
- •Active myocarditis, instable angina pectoris, exercise induced ventricular arrhythmias, decompensated heart failure, active liver disease, porphyria or elevations of serum transaminases >3 x ULN (upper limit of normal) or bilirubin >1.5 x ULN
- •Hemoglobin concentration of less than 75% of the lower limit of normal
- •Systolic blood pressure <85 mmHg
- •History or suspicion of inability to cooperate adequately
Arms & Interventions
Rehabilitation group
Experimental
15 weeks pulmonary rehabilitation program consisting of 2 weeks inpatient, 2 weeks outpatient and 11 weeks home-based rehabilitation.
Intervention: Pulmonary rehabilitation (Other)
Control group
No Intervention
Usual care
Outcomes
Primary Outcomes
Change in functional exercise capacity
Time Frame: Baseline, 4 weeks, 15 weeks
Change in six minutes-walk distance measured at baseline, after 4 weeks and at the end of the study (15 weeks after randomization).
Secondary Outcomes
- Change from baseline to 15 weeks between the rehabilitation and the control group in maximal exercise capacity(Baseline, 15 weeks)
- Difference in change over time between the rehabilitation and the control group in symptoms of anxiety and depression (HADs questionnaire)(Baseline, 4 weeks, 15 weeks)
- Difference in change over time between the rehabilitation and the control group in Isometric quadriceps force(Baseline, 4 wekes, 15 weeks)
- Difference in change over time between the rehabilitation and the control group in SF-36(Baseline, 4 weeks, 15 weeks)
- Difference in change over time between the rehabilitation and the control group in EmPHasis-10.(Baseline, 4 weeks, 15 weeks)
- Change from baseline to 15 weeks between the rehabilitation and the control group in WHO functional class(Baseline, 15 weeks)
- Difference in change over time between the rehabilitation and the control group in Borgscale at the end of the 6MWD test(Baseline, 4 weeks, 15 weeks)
- Difference in change over time between the rehabilitation and the control group in Objectively measured physical activity(Baseline, 4 weeks, 15 weeks)
- Change from baseline to 15 weeks between the rehabilitation and the control group in hemodynamics measured by echocardiography(Baseline, 15 weeks)
- Change from baseline to 15 weeks between the rehabilitation and the control group in proportion of patients who exceeded the MID in 6MWD(Baseline, 15 weeks)
- Change from baseline to 15 weeks between the rehabilitation and the control group in heart function as measured by MRI (optional)(Baseline, 15 weeks)
- adverse events(15 weeks)
Investigators
Wim Janssens
Prof. Dr.
KU Leuven
Study Sites (2)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
Evaluation of the Effectiveness of the Combined Psychological Resilience and Self-efficacy Intervention for Improving Resilience and Self-efficacy and Reducing Anxiety and Depression of Oesophageal Cancer Surgery PatientsEsophageal CancerNCT06484842Anhui Medical University123
Recruiting
Not Applicable
Pelvic physiotherapy after surgical treatment for cervical cancer1. Early stage cervical cancer<br />2. pelvic physiotherapy<br />3. pelvic floor related quality of life<br />4. micturition<br />5. defecation<br />6. sexual problems<br />(Vroeg stadium cervixcarcinoom, bekken fysiotherapie, bekkenbodem gerelateerde kwaliteit van leven, mictie-/defecatie- en seksuele problemen).NL-OMON26289Dr J.P. Roovers, gynaecologist72
Recruiting
Phase 3
Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.HIV/AIDSNCT05813964ANRS, Emerging Infectious Diseases524
Withdrawn
Phase 3
Effects of a High Viscosity Dietary Fibre, as Part of a Medically Supervised Weight Management ProgramObesityNCT01387126Canadian Center for Functional Medicine
Unknown
Phase 4
Microsurfaced Grafts in Deep Burn WoundsBurnsWound HealNCT04589442CellTherX20